FRAX(澳大利亚版)与Garvan计算器对骨折事件的预测效能:Geelong骨质疏松研究数据
基于Geelong骨质疏松研究中809名女性和821名男性(50-90岁)的10年随访数据,评估FRAX(澳大利亚版)和Garvan计算器对主要骨质疏松性骨折(MOF)、脆性骨折和髋部骨折的预测能力。两种计算器总体上低估了MOF和脆性骨折,尤其在骨量减少或骨质疏松人群中;髋部骨折预测可接受。GarvanBMD对女性脆性骨折的预测优于GarvannoBMD。
要点
- FRAX低估MOF,无论性别或是否纳入骨密度;髋部骨折预测准确,但女性纳入骨密度时预测20例,p=0.004。
- Garvan低估脆性骨折,除男性使用骨密度时预测88例,p=0.109;髋部骨折预测准确,但女性未用骨密度时预测12例,p<0.001。
- 两种计算器对MOF和脆性骨折的敏感度和特异度分析显示预测不佳,髋部骨折预测可接受。
核心结论
- FRAX和Garvan计算器总体上低估了MOF和脆性骨折,尤其在骨量减少或骨质疏松个体中;髋部骨折预测较好。
- AUROC分析提示GarvanBMD对脆性骨折的预测优于GarvannoBMD。
研究设计与样本
- 研究纳入Geelong骨质疏松研究中50-90岁的女性(n=809)和男性(n=821),随访10年,经影像学核实新发MOF、脆性骨折和髋部骨折。
- 使用FRAX和Garvan计算器分别在有和无股骨颈骨密度(BMD)情况下估计骨折风险(FRAXBMD、FRAXnoBMD、GarvanBMD、GarvannoBMD)。
- 采用卡方检验比较观察与预测骨折数的差异,并计算诊断指数。
主要发现
- 女性发生115例MOF、184例脆性骨折和42例髋部骨折;男性分别为73例、109例和17例。
- FRAX低估MOF,无论性别或是否纳入BMD;FRAX准确预测髋部骨折,但女性使用BMD时预测20例,p=0.004。
- Garvan低估脆性骨折,除男性使用BMD时预测88例,p=0.109;Garvan准确预测髋部骨折,但女性未使用BMD时预测12例,p<0.001。
- 骨折低估主要发生在骨量减少和骨质疏松组;正常BMD组中,仅男性FRAXBMD低估MOF、GarvannoBMD低估脆性骨折。
- AUROC在有和无BMD的评分间无差异,除外女性Garvan预测脆性骨折(0.696,95%CI 0.652-0.739 vs 0.668,0.623-0.712,p=0.008)和男性接近显著(0.683,0.631-0.734 vs 0.667,0.615-0.719,p=0.051)。
关键数值与推荐
- 女性:FRAX预测髋部骨折20例(使用BMD时),p=0.004;Garvan预测脆性骨折88例(男性使用BMD时),p=0.109;Garvan预测髋部骨折12例(女性未使用BMD时),p<0.001。
- AUROC:女性GarvanBMD 0.696(95%CI 0.652-0.739)vs GarvannoBMD 0.668(0.623-0.712),p=0.008;男性GarvanBMD 0.683(0.631-0.734)vs GarvannoBMD 0.667(0.615-0.719),p=0.051。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study reports that both FRAX and Garvan calculators underestimated fractures in Australian men and women, particularly in those with osteopenia or osteoporosis. Major osteoporotic fractures were poorly predicted, while both calculators performed acceptably well for hip fractures. INTRODUCTION: This study assessed the ability of the FRAX (Australia) and Garvan calculators to predict fractures in Australian women and men. METHODS: Women (n = 809) and men (n = 821) aged 50-90 years, enrolled in the Geelong Osteoporosis Study, were included. Fracture risk was estimated using FRAX and Garvan calculators with and without femoral neck bone mineral density (BMD) (FRAXBMD, FRAXnoBMD, GarvanBMD, GarvannoBMD). Incident major osteoporotic (MOF), fragility, and hip fractures over the following 10 years were verified radiologically. Differences between observed and predicted numbers of fractures were assessed using a chi-squared test. Diagnostics indexes were calculated. RESULTS: In women, 115 MOF, 184 fragility, and 42 hip fractures occurred. For men, there were 73, 109, and 17 fractures, respectively. FRAX underestimated MOFs, regardless of sex or inclusion of BMD. FRAX accurately predicted hip fractures, except in women with BMD (20 predicted, p = 0.004). Garvan underestimated fragility fractures except in men using BMD (88 predicted, p = 0.109). Garvan accurately predicted hip fractures except for women without BMD (12 predicted, p < 0.001). Fractures were underestimated primarily in the osteopenia and osteoporosis groups; MOFs in the normal BMD group were only underestimated by FRAXBMD and fragility fractures by GarvannoBMD, both in men. AUROCs were not different between scores with and without BMD, except for fragility fractures predicted by Garvan in women (0.696, 95% CI 0.652-0.739 and 0.668, 0.623-0.712, respectively, p = 0.008) and men, which almost reached significance (0.683, 0.631-0.734, and 0.667, 0.615-0.719, respectively, p = 0.051). Analyses of sensitivity and specificity showed overall that MOFs and fragility fractures were poorly predicted by both FRAX and Garvan, while hip fractures were acceptably predicted. CONCLUSIONS: Overall, the FRAX and Garvan calculators underestimated MOF and fragility fractures, particularly in individuals with osteopenia or osteoporosis. Hip fractures were predicted better by both calculators. AUROC analyses suggest that GarvanBMD performed better than GarvannoBMD for prediction of fragility fractures.
引用
- Holloway-Kew KL, Zhang Y, Betson AG, et al. How well do the FRAX (Australia) and Garvan calculators predict incident fractures? Data from the Geelong Osteoporosis Study. Osteoporos Int. 2019. PMID: 31317250. doi:10.1007/s00198-019-05088-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。